Fluzoparib (SHR-3162) (C007B-168411)

InformationFluzoparib (SHR-3162) Fluzoparib (SHR3162, HS10160) is a potent Poly (ADP-ribose) polymerase (PARP) inhibitor that shows anti-tumor activity.TargetsPARPIn vitroAll four NSCLC cell lines (A549, H460, H1299, and PC9) shows decreased viability upon exposure to fluzoparib, and the effect is time and dose dependent. Fluzoparib acts synergistically to inhibit cell growth and promote apoptosis among lung cancer cells.In vivoAn H460 cell xenograft mouse model is established to study the in vivo effects of fluzoparib and RT on tumor growth and survival. Treatment with RT + fluzoparib more effectively delayed tumor growth than treatment with either RT or fluzoparib individually. When combined with RT, fluzoparib conferres a significant survival benefit with no evidence of toxicity.Cell Research(from reference)Cell lines：human NSCLC cell lines A549, H460, H1299 and PC9 Concentrations：0–800 μM Incubation Time：24 h, 48 h, 72 h, 96 h.

Specifications and Purity: 10mM in DMSO

Molecular Formula: C22H16F4N6O2

Molecular Weight: 472.4

PubChem CID: 56649297

Isomeric SMILES: C1CN2C(=NC(=N2)C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F